Matches in SemOpenAlex for { <https://semopenalex.org/work/W2285804534> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- W2285804534 endingPage "10615" @default.
- W2285804534 startingPage "10615" @default.
- W2285804534 abstract "10615 Background: Classifying breast cancer into molecular subtypes has previously shown to be of potential use for further treatment guidance. Here we demonstrate how patients classified as high (or low) risk by MammaPrint can be further stratified into molecular subgroups by a newly developed and validated 80-gene molecular subtyping profile (BluePrint). Methods: This validation study was carried out on a gene expression dataset (Desmedt et al., ClinCRes 2007) of 198 frozen archival breast cancer samples that were also part of the TRANSBIG MammaPrint independent validation study (Buyse et al., JNCI 2006). These patients from 5 European hospitals had T1-2N0M0 invasive breast cancer, median age 47 years, median follow-up 14 years, without adjuvant treatment. Results: The 70-gene MammaPrint profile classified 124 out of 187 breast tumors (66%) as high risk and 63 (34%) as low risk. The 124 MammaPrint high-risk tumors were then further substratified with BluePrint into 48% (60) luminal-type, 21% (26) as ERBB2-type and 31% (38) as basal-type. Kaplan Meier analysis of these substratified groups shows nearly identical 10 year DMFS rates: luminal-type tumors 66%, ERBB2-type tumors 53%, basal-type tumors 62%, respectively, a similar survival as the original unstratified MammaPrint high-risk group (64%). Similarly, BluePrint stratified low-risk MammaPrint patients (63) all showed invariable good outcome (10 yr DMFS > 95%), including no distant metastases for basal and ERBB2-type (small) subgroups for a 10-year time period. Conclusions: The molecular subtyping profile BluePrint can classify MammaPrint high-risk breast tumors into biologically different molecular subgroups. We and others have shown that breast tumors of distinct molecular subtype have different benefit from (neo)adjuvant chemotherapy, ranging from minimal response in luminal- to substantial response for ERBB2- and basal-type tumors. Further substratification of MammaPrint high-risk patients may therefore be useful for developing subtype specific treatment regimens and potentially useful for future treatment decisions. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Agendia" @default.
- W2285804534 created "2016-06-24" @default.
- W2285804534 creator A5032131062 @default.
- W2285804534 creator A5055013846 @default.
- W2285804534 creator A5062240415 @default.
- W2285804534 creator A5073937187 @default.
- W2285804534 creator A5075755065 @default.
- W2285804534 date "2010-05-20" @default.
- W2285804534 modified "2023-10-18" @default.
- W2285804534 title "Substratification of 70-gene high-risk breast cancers with a validated 80-gene molecular subtyping profile." @default.
- W2285804534 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.10615" @default.
- W2285804534 hasPublicationYear "2010" @default.
- W2285804534 type Work @default.
- W2285804534 sameAs 2285804534 @default.
- W2285804534 citedByCount "0" @default.
- W2285804534 crossrefType "journal-article" @default.
- W2285804534 hasAuthorship W2285804534A5032131062 @default.
- W2285804534 hasAuthorship W2285804534A5055013846 @default.
- W2285804534 hasAuthorship W2285804534A5062240415 @default.
- W2285804534 hasAuthorship W2285804534A5073937187 @default.
- W2285804534 hasAuthorship W2285804534A5075755065 @default.
- W2285804534 hasConcept C121608353 @default.
- W2285804534 hasConcept C126322002 @default.
- W2285804534 hasConcept C143998085 @default.
- W2285804534 hasConcept C199360897 @default.
- W2285804534 hasConcept C41008148 @default.
- W2285804534 hasConcept C530470458 @default.
- W2285804534 hasConcept C71924100 @default.
- W2285804534 hasConcept C83852419 @default.
- W2285804534 hasConceptScore W2285804534C121608353 @default.
- W2285804534 hasConceptScore W2285804534C126322002 @default.
- W2285804534 hasConceptScore W2285804534C143998085 @default.
- W2285804534 hasConceptScore W2285804534C199360897 @default.
- W2285804534 hasConceptScore W2285804534C41008148 @default.
- W2285804534 hasConceptScore W2285804534C530470458 @default.
- W2285804534 hasConceptScore W2285804534C71924100 @default.
- W2285804534 hasConceptScore W2285804534C83852419 @default.
- W2285804534 hasIssue "15_suppl" @default.
- W2285804534 hasLocation W22858045341 @default.
- W2285804534 hasOpenAccess W2285804534 @default.
- W2285804534 hasPrimaryLocation W22858045341 @default.
- W2285804534 hasRelatedWork W1971465952 @default.
- W2285804534 hasRelatedWork W1983615930 @default.
- W2285804534 hasRelatedWork W2406547867 @default.
- W2285804534 hasRelatedWork W2567847592 @default.
- W2285804534 hasRelatedWork W2893670326 @default.
- W2285804534 hasRelatedWork W3163257735 @default.
- W2285804534 hasRelatedWork W3165409583 @default.
- W2285804534 hasRelatedWork W377899687 @default.
- W2285804534 hasRelatedWork W4312675761 @default.
- W2285804534 hasRelatedWork W4313469582 @default.
- W2285804534 hasVolume "28" @default.
- W2285804534 isParatext "false" @default.
- W2285804534 isRetracted "false" @default.
- W2285804534 magId "2285804534" @default.
- W2285804534 workType "article" @default.